Welcome to our dedicated page for Avanos Medical news (Ticker: AVNS), a resource for investors and traders seeking the latest updates and insights on Avanos Medical stock.
Avanos Medical, Inc. (NYSE: AVNS) delivers innovative medical device solutions addressing critical healthcare challenges in pain management, recovery, and digestive health. This page provides investors and industry professionals with timely updates on the company’s latest developments, strategic initiatives, and clinical advancements.
Access official press releases, earnings reports, and regulatory filings alongside analysis of product launches and partnerships. Track Avanos Medical’s progress in advancing non-opioid therapies and life-sustaining nutritional support systems designed for hospital and home care settings.
Key updates include developments in cold compression technology, feeding tube innovations, and operational efficiency initiatives under the company’s ongoing transformation. All content is sourced directly from Avanos Medical and verified financial disclosures to ensure accuracy.
Bookmark this page for streamlined access to AVNS news that impacts clinical practice and investment decisions. Check regularly for updates on breakthrough medical technologies and their global healthcare applications.
GAME READY, an Avanos Medical (NYSE: AVNS) brand, has announced a partnership with NFL defensive end Nick Bosa of the San Francisco 49ers. As the Official Recovery Partner of Bosa, GAME READY will integrate its cold and compression therapy technology into his training and recovery regimen. This collaboration aims to showcase the brand's commitment to supporting elite performance through advanced recovery solutions.
The partnership includes collaborative content, product promotions, and appearances by Bosa across various media platforms. It highlights the importance of effective recovery for peak athletic performance and reinforces GAME READY's position as a trusted brand among top athletes globally.
Avanos Medical (NYSE: AVNS) reported Q2 2024 financial results, showing positive growth and progress in its transformation objectives. Key highlights include:
- Total net sales from continuing operations were $171.7 million, up 1.4% year-over-year
- Net income from continuing operations was $4.3 million, compared to a $4.3 million loss last year
- Adjusted diluted EPS from continuing operations was $0.34, up from $0.24 in Q2 2023
- Adjusted EBITDA increased to $26.8 million from $22.9 million last year
The company's Digestive Health portfolio led growth, while Pain Management and Recovery showed improvement. Avanos maintains its 2024 outlook, expecting revenue between $685-$705 million and adjusted diluted EPS of $1.30-$1.45 from continuing operations.
Avanos Medical, Inc. (NYSE: AVNS) has announced a webcast conference call to discuss its second quarter 2024 financial results on Wednesday, July 31 at 9 a.m. ET. The company will release its financial results before the market opens on the same day. CEO Joe Woody and CFO Michael Greiner will host the call. Investors can join via phone or webcast through the company's website. A replay will be available for one week after the call.
Avanos Medical is a medical technology company focused on delivering clinically superior medical device solutions. The company is committed to addressing important healthcare needs, including providing nutrition solutions and reducing opioid use in post-surgical recovery.
Avanos Medical has appointed Indrani Franchini as a new independent member of its board of directors. She brings extensive experience from global companies, including roles at Alnylam Pharmaceuticals, Alexion Pharmaceuticals, Hess , and Pfizer. This addition expands the board to six directors, with five being independent and a diverse representation, including three women. Franchini's legal and compliance expertise is expected to aid Avanos in addressing critical healthcare needs and advancing its mission.
Avanos Medical, Inc. has appointed Sig Delgado as Senior Vice President, Integrated Supply Chain. Delgado, with over 20 years of experience in manufacturing and supply chain in the medical device industry, will lead the continuous improvement efforts in the company's global supply chain. His expertise will play a important role in achieving the company's transformation goals and enhancing its existing foundation in this area.
Avanos Medical, Inc. announced their first quarter 2024 financial results, showing positive growth in net sales, income, and earnings per share. The company highlighted progress in their transformation initiative, margin expansion targets, and growth objectives in various portfolios. Despite a decrease in gross margin due to transformation costs, Avanos reported an increase in adjusted EBITDA and operating profit. The company also provided a 2024 outlook with revenue estimates and non-GAAP financial measures.
FAQ
What is the current stock price of Avanos Medical (AVNS)?
What is the market cap of Avanos Medical (AVNS)?
